Indian Drug maker Dr. Datsons Labs has received the proposal to supply the Artemisinin-based combination therapies (ACTs) to the Clinton Health Access Initiative (CHAI), the healthcare project of the Clinton Foundation. Dr. Datsons Labs will be making a significant deal though there is a minimum pricing that the company will be working on.
The volume will be huge because it will be supplied to most of the African countries. In the UNITAID-CHAI Malaria Treatment Project 2015, other big players such as Cipla, Ipea & other Indian players are already on the approved list of The Clinton Health Access Initiative (CHAI) to supply the drugs.
Dr. Datsons Labs is a leading research based integrated pharmaceutical company with established research, manufacturing and marketing capabilities. It is R&D focused, has a multi product portfolio with state of the art manufacturing facilities, and is set to become a marketing conglomerate across the globe.
